Results 201 to 210 of about 21,108 (240)

Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD). [PDF]

Indian J Endocrinol Metab
Das BK, Das S, Meher D, Choudhury AK, Padhee S, Sahu SK, Sahoo D, Prusty B, Agarwal V.   +8 more
europepmc   +1 more source

Off-label use of dapagliflozin in a dog with recurrent calcium oxalate urolithiasis: a case report. [PDF]

BMC Vet Res
Pakhawala J.
europepmc   +1 more source

Aqueous <i>Artemisia herba-alba</i> Asso Preparation as a Botanical Adjunct to Dapagliflozin: Enhanced Glycemic Control in Streptozotocin-Induced Diabetic Rats. [PDF]

Pharmaceutics
Hailat MM, Al-Karkhi MM, Al-Qaisi NT, Shalash M, Abu Dayyih W, Hourani W, Assab MA, Farhan AB, Dayyih ARA, Talalah SB, Talalah AB.   +10 more
europepmc   +1 more source

The Real-World Use of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction Newly Initiated on Dapagliflozin: An EVOLUTION-HF CEE-BA Study (Results from the Baltic Cohort). [PDF]

Medicina (Kaunas)
Žaliaduonytė D, Orda P, Pullisaar O, Blöndal M, Kavaliauskienė R, Laukaitienė J, Pontaga N, Maneikienė V, Strēlnieks A, Trušinskis K, Uuetoa T, Stirna V, Hedman A.   +12 more
europepmc   +1 more source

Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study. [PDF]

Cureus
Alzahrani M, Alsudairy N, Al Asmari Z, Basubrain L, Saad H, Abdullatif A, Alawashiz Z, Alsulami N, Alrezqi M.   +8 more
europepmc   +1 more source

Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Li X, Zhang Y, Wang L, Zhao Y.
europepmc   +1 more source

SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications. [PDF]

Mol Biomed
Zheng XT, Xie HY, Wang XH, Zhao Y, Yang JY, Liu YX, Yuan XL, Tang HF, Jiang ZS, Hu HJ.   +9 more
europepmc   +1 more source

Durable Insulin-free Remission in A-β+ Ketosis-Prone Diabetes With SGLT2 Inhibition: A Case Report With Longitudinal C-Peptide and CGM Data. [PDF]

Clin Med Insights Endocrinol Diabetes
Ahmadjonov A, Malik DE, Kuziev O, Toshova S, Smerat A, Adi M, Ashraf A.   +6 more
europepmc   +1 more source

Corrigendum to "Randomized Controlled Trial of Dapagliflozin for Post-Transplant Diabetes Mellitus in Renal Transplant Recipients" [<i>Kidney International Reports</i> Volume 11, Issue 7, July 2026, 106559]. [PDF]

Kidney Int Rep
Lin L, Li J, Zhou J, Gao X, Lin S, Wang D, Chen P.   +6 more
europepmc   +1 more source

A Review of the Current Literature Regarding Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Preserved Ejection Fraction and Timing of Initiating Therapy. [PDF]

Cureus
Sahyouni M, Lodha C, Joseph Varughese V.
europepmc   +1 more source